After reporting FY2016 revenues below market expectations, Myriad discussed plans to increase sales of Prolaris, Vectra DA, EndoPredict, GeneSight, and myChoice HRD.
The company credited the increased revenues to a 12 percent rise in the number of Oncotype Dx tests delivered.
The firm completed its acquisition of Nanosphere on June 30, and received FDA clearance and CE-IVD marking for the Aries M1 system on July 6.
Revenues from the company’s molecular diagnostics business grew 6 percent, driven by continued strength in sales of women's health products.
The company said it completed about 54,000 Cologuard tests in Q2, and that the cumulative number of physicians ordering the test since its launch has risen to 41,000.
Danaher Q2 net earnings fell 5 percent to $656.7 million, or $.94 per diluted share, from $695.7 million, or $.97 per diluted share, a year ago.
Luminex's anticipated FY 2016 revenue growth of 6 percent to 9 percent could potentially push higher into the double digits following the integration of Nanosphere.